New cell therapy takes on virus-driven blood cancers in tiny early trial
NCT ID NCT05635591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new treatment called KSD-101 in 9 adults with blood cancers linked to the Epstein-Barr virus. The main goal is to find a safe dose and see if it shrinks tumors. Participants must have tried standard treatments without success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV-ASSOCIATED HAEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Li Chunrui
Wuhan, Hubei, 430000, China